检索范围:
排序: 展示方式:
Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives
Felicitas THOL, Arnold GANSER
《医学前沿(英文)》 2010年 第4卷 第4期 页码 356-362 doi: 10.1007/s11684-010-0220-5
FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches
《医学前沿(英文)》 2022年 第16卷 第6期 页码 896-908 doi: 10.1007/s11684-022-0944-z
关键词: acute myeloid leukemia FGF13 prognosis immune-related genes bone marrow niches
《医学前沿(英文)》 2022年 第16卷 第4期 页码 627-636 doi: 10.1007/s11684-020-0815-4
关键词: RUNX1 gene mutation acute myeloid leukemia transcriptional repression DNA methylation
《医学前沿(英文)》 2023年 第17卷 第4期 页码 685-698 doi: 10.1007/s11684-022-0942-1
关键词: acute myeloid leukemia acyl-CoA synthetase long chain family member 5 Wnt3a palmitoylation ABT-199
Chimeric antigen receptor T cell therapies for acute myeloid leukemia
Bin Gu, Jianhong Chu, Depei Wu
《医学前沿(英文)》 2020年 第14卷 第6期 页码 701-710 doi: 10.1007/s11684-020-0763-z
null
《医学前沿(英文)》 2017年 第11卷 第3期 页码 440-444 doi: 10.1007/s11684-017-0523-x
Philadelphia chromosome-positive acute myeloid leukemia is controversial and difficult to distinguish from the blast phase of chronic myeloid leukemia. As a myeloid neoplasm, rare cases of this leukemia manifest multiple soft-tissue tumors or bone lytic lesions. In this paper, we describe a 49-year-old male patient who had an abrupt onset with sharp chest pain, fever, fatigue, emaciation, and splenomegaly. 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) result showed diffuse and uneven hypermetabolic lesions in the bone marrow with peripheral bone marrow expansion, multiple soft tissue neoplasms with high 18F-FDG uptake, and lytic bone lesions. Bone marrow smear and biopsy detected aberrant blast cells expressing myeloid rather than lymphoid immunophenotype marker. For the existence of Philadelphia chromosome and BCR-ABL1 fusion gene together with complex chromosome abnormalities, a diagnosis of Philadelphia-positive acute myeloid leukemia was made, although the type (de novo or blast crisis) remained unclear.
关键词: Philadelphia chromosome acute myeloid leukemia mass osteolysis positron emission tomography
Bingshan Liu, Roshni Narurkar, Madhura Hanmantgad, Wahib Zafar, Yongping Song, Delong Liu
《医学前沿(英文)》 2018年 第12卷 第5期 页码 593-599 doi: 10.1007/s11684-018-0635-y
Conventional combination therapies have not resulted in considerable progress in the treatment of acute myeloid leukemia (AML). Elderly patients with AML and poor risk factors have grave prognosis. Midostaurin has been recently approved for the treatment of FLT-3-mutated AML. Venetoclax, a BCL-2 inhibitor, has been approved for the treatment of relapsed and/or refractory chronic lymphoid leukemia. Clinical trials on applying venetoclax in combination with cytarabine and other agents to treat various hematological malignancies are currently underway. Here, we present a case of a male patient with poor performance status and who developed AML following allogeneic hematopoietic stem cell transplant for high-risk myelodysplasia. The patient with high risk AML achieved complete response to the combined treatment regimen of low-dose cytarabine and venetoclax. Furthermore, we reviewed current clinical trials on the use of venetoclax for hematological malignancies.
关键词: venetoclax cytarabine AML leukemia
Xiaoxiao Chen, Yanjing Tang, Jing Chen, Ru Chen, Longjun Gu, Huiliang Xue, Ci Pan, Jingyan Tang, Shuhong Shen
《医学前沿(英文)》 2019年 第13卷 第3期 页码 378-387 doi: 10.1007/s11684-018-0658-4
null
《医学前沿(英文)》 2015年 第9卷 第4期 页码 412-420 doi: 10.1007/s11684-015-0423-x
Genetic mutations are considered to drive the development of acute myeloid leukemia (AML). With the rapid progress in sequencing technologies, many newly reported genes that are recurrently mutated in AML have been found to govern the initiation and relapse of AML. These findings suggest the need to distinguish the driver mutations, especially the most primitive single mutation, from the subsequent passenger mutations. Recent research on DNA methyltransferase 3A (DNMT3A) mutations provides the first proof-of-principle investigation on the identification of preleukemic stem cells (pre-LSCs) in AML patients. Although DNMT3A mutations alone may only transform hematopoietic stem cells into pre-LSCs without causing the full-blown leukemia, the function of this driver mutation appear to persist from AML initiation up to relapse. Therefore, identifying and targeting preleukemic mutations, such as DNMT3A mutations, in AML is a promising strategy for treatment and reduction of relapse risk.
关键词: preleukemic stem cell acute myeloid leukemia relapse DNMT3A
Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era
null
《医学前沿(英文)》 2012年 第6卷 第2期 页码 204-211 doi: 10.1007/s11684-012-0202-x
We evaluated the outcomes of chronic myeloid leukemia (CML) patients in three clinical phases, namely, chronic (CP), accelerated (AP), and blast (BP) phases, receiving imatinib treatment. The single-institution treatment experiences of Chinese patients with CML were presented. A total of 275 CML patients (CP, 210; AP, 24; and BP, 41) who received imatinib between February 2001 and April 2008 were enrolled in this study. We evaluated the responses (hematologic, cytogenetic, and molecular), overall survival (OS), treatment event-free survival (EFS), and prognostic factors of outcome. At the cut-off point, the complete cytogenetic response (CCyR) and complete molecular response rates of patients in the CP were 84.7% and 61.9%, respectively, which were significantly higher than those of patients in the AP (50% and 29.1%, respectively, both P<0.001) and BP (24.3% and 9.7%, respectively, both P<0.001). The estimated five-year OS and five-year EFS rates were 93.2% and 86.4% for CP patients, as well as 64.5% and 50.9% for AP patients, which were significantly higher than those for BP patients (P<0.001). In CP patients, univariate analysis revealed that early treatment with imatinib, achieving CCyR within 12 months, additional cytogenetic abnormalities, and kinase domain mutations were associated with the treatment outcome. More patients are needed to carry out multivariate analysis.
关键词: imatinib chronic myeloid leukemia complete cytogenetic response
Meng Lv, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang, Xiaodong Mo
《医学前沿(英文)》 2019年 第13卷 第6期 页码 667-679 doi: 10.1007/s11684-019-0702-z
关键词: acute graft-versus-host disease chronic graft-versus-host disease National Institutes of Health consensus criteria acute myeloid leukemia anti-thymocyte globulin
null
《医学前沿(英文)》 2011年 第5卷 第1期 页码 45-52 doi: 10.1007/s11684-011-0117-y
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia. In past decades, intensive studies on the biology and treatment of this disease have resulted in a remarkably thorough understanding of its pathogenesis and improvement of treatment outcomes. In particular, the introduction of all-trans retinoic acid to conventional chemotherapy improved dramatically the remission and survival rates of APL patients and consequently became the major treatment modality for it. In the last decade, the groundbreaking development of arsenic further improved the survival rate of APL patients. As the most active agent in APL, arsenic directly degrades the PML-RARα fusion transcript, leading to the differentiation and apoptosis of leukemia cells and the potential eradication of APL leukemia-initiating cells (LICs), thus making the disease a potentially curable type of leukemia. More notably, the recent development of oral arsenic compounds may further enhance not only clinical outcomes but also the convenience of patients, which may dramatically change the APL clinical scenario in the near future.
关键词: acute promyelocytic leukemia arsenic all-trans retinoic acid survival
《医学前沿(英文)》 2023年 第17卷 第3期 页码 518-526 doi: 10.1007/s11684-022-0958-6
关键词: acute lymphoblastic leukemia child venous thromboembolism epidemiology clinical characteristic risk factor
Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia
null
《医学前沿(英文)》 2012年 第6卷 第4期 页码 416-420 doi: 10.1007/s11684-012-0224-4
Acute lymphoblastic leukemia includes T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acute lymphoblastic leukemia (B-ALL). In children, T-ALL usually has a worse prognosis than B-ALL, although childhood T-ALL prognoses have improved remarkably. The varying outcomes among T-ALL cases suggest that an unrecognized biological heterogeneity may contribute to chemo-resistance. Deep exploration of T-lymphocyte development in recent years has found a subgroup of patients with a phenotype that resembles early T-cell precursor, which confers a much poorer prognosis than any other form of T-ALL. This novel subtype of T-ALL was called early T-cell precursor acute lymphoblastic leukemia (ETP-ALL). Flow cytometry data from T-ALL patients enrolled in Shanghai Children’s Medical Center between July 2002 and October 2010 were assessed according to Dr. Campana’s protocol. Among total 89 T-ALL cases, 74 cases had enough immunophenotype data available to differentiate between ETP (CD1a-, CD8-, CD5dim, at least one marker of stem cell or myeloid lineage) and non-ETP. From these 74 subjects, 12 ETP-ALL cases (16.2%) were identified. The event-free survival (EFS) rate at 66.8 months was 11.1%±10.1% for ETP-ALL and 57.6%±5.6% for non-ETP-ALL (P=0.003). The overall survival rates were 13.3%±11.0% for ETP-ALL and 64.7%±6.3% for non-ETP-ALL (P=0.002). Our findings demonstrate that early T-cell precursor leukemia is a very high-risk subtype of acute lymphoblastic leukemia with poor prognosis.
关键词: acute lymphoblastic leukemia early T precursor prognosis
Mutation profiling of 16 candidate genes in
Yang Zhang, Fang Wang, Xue Chen, Wenjing Liu, Jiancheng Fang, Mingyu Wang, Wen Teng, Panxiang Cao, Hongxing Liu
《医学前沿(英文)》 2019年 第13卷 第2期 页码 229-237 doi: 10.1007/s11684-018-0616-1
标题 作者 时间 类型 操作
Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives
Felicitas THOL, Arnold GANSER
期刊论文
expression pattern of mutations coordinated by target repression and promoter hypermethylation in acutemyeloid leukemia
期刊论文
ACSL5, a prognostic factor in acute myeloid leukemia, modulates the activity of Wnt/-catenin signaling
期刊论文
Chimeric antigen receptor T cell therapies for acute myeloid leukemia
Bin Gu, Jianhong Chu, Depei Wu
期刊论文
Philadelphia chromosome-positive acute myeloid leukemia with masses and osteolytic lesions: finding of
null
期刊论文
Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloidleukemia: a case report
Bingshan Liu, Roshni Narurkar, Madhura Hanmantgad, Wahib Zafar, Yongping Song, Delong Liu
期刊论文
Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acutemyeloid leukemia
Xiaoxiao Chen, Yanjing Tang, Jing Chen, Ru Chen, Longjun Gu, Huiliang Xue, Ci Pan, Jingyan Tang, Shuhong Shen
期刊论文
methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia
null
期刊论文
disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acutemyeloid leukemia
Meng Lv, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang, Xiaodong Mo
期刊论文
Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research
null
期刊论文
Venous thromboembolism in children with acute lymphoblastic leukemia in China: a report from the Chinese
期刊论文
Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia
null
期刊论文